The Mayo Clinic and Roswell Park regimens were selected as reference regimens for NO16968 because they were widely used and known to have similar efficacy in this setting. 5 In the intervening years, ...

Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer. This ...

Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil ...

Capecitabine is metabolized preferentially in tumor tissue to the cytotoxic moiety 5-FU by the enzyme thymidine phosphorylase, which is upregulated by other cytotoxic agents and by x-rays.

Capecitabine is an oral fluoropyrimidine prodrug that is selectively converted within cancer cells to the active drug 5-fluorouracil. Clinical trials have indicated that capecitabine is a safe and ...

Capecitabine (Xeloda, Hoffmann–La Roche), an oral prodrug of fluorouracil, has been shown to be efficacious as adjuvant chemotherapy in patients with gastrointestinal cancer. 5–7 However, its ...

The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan ...

For patients who received neratinib plus capecitabine, median OS was 21 months (95% CI, 17.7-23.8) compared with 18.7 months (95% CI, 15.5-21.2) for those who received lapatinib plus capecitabine ...

Capecitabine is a chemotherapy drug sold under the brand name Xeloda. It’s sometimes used as a treatment for gallbladder cancer.

Capecitabine can induce sufficient hemolysis to cause an isolated rise in bilirubin levels (reported in 20–70% of patients), which can often lead to a degree of confusion over appropriate dose ...